CY1124657T1 - ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ - Google Patents

ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ

Info

Publication number
CY1124657T1
CY1124657T1 CY20211100636T CY211100636T CY1124657T1 CY 1124657 T1 CY1124657 T1 CY 1124657T1 CY 20211100636 T CY20211100636 T CY 20211100636T CY 211100636 T CY211100636 T CY 211100636T CY 1124657 T1 CY1124657 T1 CY 1124657T1
Authority
CY
Cyprus
Prior art keywords
formulations
patches
pthrp analog
bone
methods
Prior art date
Application number
CY20211100636T
Other languages
English (en)
Inventor
Gary Hattersley
Alan Harris
Jamal SAEH
Ehab Hamed
Kenneth Brown
Daniel Dohmeier
Ying Zhang
Lisa Dick
Joan Moseman
Original Assignee
Radius Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health, Inc. filed Critical Radius Health, Inc.
Publication of CY1124657T1 publication Critical patent/CY1124657T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται σκευάσματα αναλόγου PTHrP για τη διαδερμική παροχή μίας θεραπευτικώς αποτελεσματικής ποσότητας ενός αναλόγου PTHrP, καθώς και διαδερμικά επιθέματα που παρασκευάζονται χρησιμοποιώντας αυτά τα σκευάσματα, μέθοδοι παρασκευής των αποκαλυπτομένων σκευασμάτων και επιθεμάτων, και μέθοδοι χρήσης αυτών των σκευασμάτων και επιθεμάτων για την αγωγή οστεοπόρωσης, οστεοπενίας, οστεοαρθρίτιδας, και/ή οστικών καταγμάτων, τη βελτίωση της οστικής πυκνότητας (BMD), τη βελτίωση της βαθμολογίας δοκιδωτού στού (TBS), και την αγωγή, πρόληψη, και/ή τον περιορισμό των οστικών καταγμάτων.
CY20211100636T 2015-10-09 2021-07-14 ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ CY1124657T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239801P 2015-10-09 2015-10-09
US201562239774P 2015-10-09 2015-10-09
US201562239773P 2015-10-09 2015-10-09
US201662324336P 2016-04-18 2016-04-18
US201662353249P 2016-06-22 2016-06-22
US201662396196P 2016-09-18 2016-09-18
PCT/US2016/056196 WO2017062922A1 (en) 2015-10-09 2016-10-08 Formulations of pthrp analogues, transdermal patches thereof, and uses thereof

Publications (1)

Publication Number Publication Date
CY1124657T1 true CY1124657T1 (el) 2022-07-22

Family

ID=58488710

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100636T CY1124657T1 (el) 2015-10-09 2021-07-14 ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ

Country Status (22)

Country Link
US (1) US20190091138A1 (el)
EP (2) EP3909566A1 (el)
JP (3) JP6867379B2 (el)
KR (1) KR20180067573A (el)
CN (2) CN108697881A (el)
AU (2) AU2016334378B2 (el)
BR (1) BR112018007159A2 (el)
CA (1) CA3000533C (el)
CY (1) CY1124657T1 (el)
DK (1) DK3359241T3 (el)
ES (1) ES2881461T3 (el)
HR (1) HRP20211127T1 (el)
HU (1) HUE055658T2 (el)
IL (2) IL287604B2 (el)
LT (1) LT3359241T (el)
MX (1) MX2018004192A (el)
PL (1) PL3359241T3 (el)
PT (1) PT3359241T (el)
RS (1) RS62394B1 (el)
SG (1) SG11201802871UA (el)
SI (1) SI3359241T1 (el)
WO (1) WO2017062922A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265115B1 (en) * 2015-03-03 2022-06-22 Radius Health, Inc. Abaloparatide combined with alendronate for reducing non-vertebral bone fractures
EP3481414B1 (en) 2016-04-18 2021-11-03 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
WO2019059303A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
CN107674113A (zh) * 2017-10-20 2018-02-09 广东医科大学 一种小分子活性肽及其制备方法、及采用该活性肽的透皮贴剂的制备方法与其用途
CN110054679B (zh) * 2018-01-18 2021-05-04 成都圣诺生物制药有限公司 一种合成Abaloparatide的方法
CN109602911B (zh) * 2019-01-09 2020-11-10 厦门大学 硫酸钙晶须或其组合物在制备皮肤促渗剂中的用途
CN113453704A (zh) 2019-02-28 2021-09-28 雷迪厄斯健康公司 阿巴帕肽的透皮递送系统及其使用方法
WO2021051082A1 (en) * 2019-09-12 2021-03-18 Radius Health, Inc. Methods of improving spinal fusion with abaloparatide
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
US12029562B2 (en) 2021-04-14 2024-07-09 Satio, Inc. Dermal patch system
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
WO2022249108A1 (en) * 2021-05-25 2022-12-01 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
AU2007225056A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
RS56164B1 (sr) * 2006-10-03 2017-11-30 Radius Health Inc Stabilna kompozicija koja sadrži pthrp i njene upotrebe
WO2009054988A1 (en) * 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
WO2010111617A2 (en) * 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2790923C (en) * 2010-02-24 2017-10-31 Toshiyuki Matsudo Micro-needle device and preparation method
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
MX2013012349A (es) * 2011-04-22 2014-07-09 Radius Health Inc Metodo para suministro de farmaco para pth, pthrp y peptidos relacionados.
US9623087B2 (en) * 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
CN102526220A (zh) * 2012-01-10 2012-07-04 上海市中医医院 一种治疗期前收缩的中药贴剂及其制备方法和应用
US9581438B2 (en) * 2012-12-31 2017-02-28 General Electric Company Systems and methods for control of a non-destructive testing system
BR112016000937A8 (pt) * 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CN108135962A (zh) * 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂

Also Published As

Publication number Publication date
IL287604B2 (en) 2024-04-01
PL3359241T3 (pl) 2021-12-20
JP6867379B2 (ja) 2021-04-28
SI3359241T1 (sl) 2021-11-30
HUE055658T2 (hu) 2021-12-28
CN108697881A (zh) 2018-10-23
AU2016334378B2 (en) 2021-12-02
CN115025068A (zh) 2022-09-09
ES2881461T3 (es) 2021-11-29
CA3000533C (en) 2023-10-17
JP7146011B2 (ja) 2022-10-03
DK3359241T3 (da) 2021-07-19
LT3359241T (lt) 2021-10-11
KR20180067573A (ko) 2018-06-20
EP3909566A1 (en) 2021-11-17
IL258441B (en) 2021-12-01
US20190091138A1 (en) 2019-03-28
EP3359241A1 (en) 2018-08-15
SG11201802871UA (en) 2018-05-30
RS62394B1 (sr) 2021-10-29
EP3359241A4 (en) 2019-06-26
WO2017062922A1 (en) 2017-04-13
EP3359241B1 (en) 2021-04-14
IL258441A (en) 2018-05-31
AU2016334378A1 (en) 2018-04-19
BR112018007159A2 (pt) 2018-11-06
JP2021119141A (ja) 2021-08-12
CA3000533A1 (en) 2017-04-13
IL287604B1 (en) 2023-12-01
MX2018004192A (es) 2018-09-26
JP2022174274A (ja) 2022-11-22
AU2021269361A1 (en) 2021-12-16
HRP20211127T1 (hr) 2021-10-15
PT3359241T (pt) 2021-07-21
IL287604A (en) 2021-12-01
JP2018536631A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
CY1124657T1 (el) ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
PH12020550901A1 (en) Macrocyclic compounds for treating disease
TN2017000243A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12019501896A1 (en) Therapeutic dendrimers
MX2021006734A (es) Metodo para tratar el cancer.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
NZ761519A (en) Nlrp3 modulators
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
IL279208A (en) Therapeutic methods and compositions for the treatment of pancreatic cancer using 6, 8-bis(benzylsulfenyl)octanoic acid
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
EP3999112A4 (en) TUMOR VACCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF CANCER